Bloomberg Law
Dec. 1, 2022, 8:08 AM

Roche Drug for Alzheimer’s Cleared Less Amyloid Than Hoped (1)

Naomi Kresge
Naomi Kresge
Bloomberg News

Roche Holding AG’s experimental Alzheimer’s disease drug was far less effective than hoped at clearing a toxic protein from the brain, according to findings from two studies that may explain why it failed when a rival therapy succeeded.

Amyloid, an abnormal protein in Alzheimer’s patients’ brains, dropped to a target threshold in only about a quarter of treated patients, Roche said Wednesday in a presentation at the Clinical Trials in Alzheimer’s Disease conference in San Francisco. A smaller study had suggested that the drug could hit that target in about half of patients.

The results scuttle hopes for gantenerumab ...

Learn more about Bloomberg Law or Log In to keep reading:

Learn About Bloomberg Law

AI-powered legal analytics, workflow tools and premium legal & business news.

Already a subscriber?

Log in to keep reading or access research tools.